Published in Lancet on July 05, 2003
A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci U S A (2007) 3.82
The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br J Pharmacol (2005) 2.73
Maximizing survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure population. Circulation (2009) 2.34
Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ (2013) 2.26
Signaling effectors underlying pathologic growth and remodeling of the heart. J Clin Invest (2013) 2.06
Carvedilol and its new analogs suppress arrhythmogenic store overload-induced Ca2+ release. Nat Med (2011) 1.88
Primary and secondary prevention of cardiovascular diseases: a practical evidence-based approach. Mayo Clin Proc (2009) 1.88
Beta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation. Proc Natl Acad Sci U S A (2008) 1.67
Life and death of a cardiac calcium spark. J Gen Physiol (2013) 1.65
Beta2-adrenoceptor signaling is required for the development of an asthma phenotype in a murine model. Proc Natl Acad Sci U S A (2009) 1.53
Bisoprolol vs. carvedilol in elderly patients with heart failure: rationale and design of the CIBIS-ELD trial. Clin Res Cardiol (2008) 1.53
Safety of aprotinin in congenital heart operations: results from a large multicenter database. Ann Thorac Surg (2010) 1.48
New perspectives regarding β(2) -adrenoceptor ligands in the treatment of asthma. Br J Pharmacol (2011) 1.46
Trends and inequities in beta-blocker prescribing for heart failure. Br J Gen Pract (2008) 1.41
Surgical ventricular restoration: the RESTORE Group experience. Heart Fail Rev (2004) 1.37
Modulating fatty acid oxidation in heart failure. Cardiovasc Res (2011) 1.37
Arrhythmogenic effects of beta2-adrenergic stimulation in the failing heart are attributable to enhanced sarcoplasmic reticulum Ca load. Circ Res (2008) 1.25
Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE. Eur J Heart Fail (2009) 1.25
[Guidelines for therapy of chronic heart failure]. Z Kardiol (2005) 1.24
Modulation of beta-adrenergic receptor signaling in heart failure and longevity: targeting adenylyl cyclase type 5. Heart Fail Rev (2010) 1.24
Alpha-1-adrenergic receptors: targets for agonist drugs to treat heart failure. J Mol Cell Cardiol (2010) 1.23
Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. Eur J Heart Fail (2011) 1.20
Trends in catheter ablation for atrial fibrillation in the United States. J Hosp Med (2009) 1.17
The right ventricle in pulmonary arterial hypertension: disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure. Circ Res (2014) 1.14
Chronic heart failure, chronotropic incompetence, and the effects of beta blockade. Heart (2005) 1.13
Temporal trends in treatment and outcomes for advanced heart failure with reduced ejection fraction from 1993-2010: findings from a university referral center. Circ Heart Fail (2013) 1.12
β-Adrenergic receptor subtype signaling in heart: from bench to bedside. Acta Pharmacol Sin (2012) 1.10
Geographic variation in cardioprotective antihypertensive medication usage in dialysis patients. Am J Kidney Dis (2011) 1.09
Ryanodine receptor-mediated arrhythmias and sudden cardiac death. Pharmacol Ther (2009) 1.08
Atrial fibrillation in congestive heart failure. Heart Fail Clin (2010) 1.07
Beta blockers for elective surgery in elderly patients: population based, retrospective cohort study. BMJ (2005) 1.06
Dietary fish intake and incident atrial fibrillation (from the Women's Health Initiative). Am J Cardiol (2010) 1.05
Years-needed-to-treat to add 1 year of life: a new metric to estimate treatment effects in randomized trials. Eur J Heart Fail (2009) 1.03
Carvedilol in hypertension treatment. Vasc Health Risk Manag (2008) 1.02
Junctin and the histidine-rich Ca2+ binding protein: potential roles in heart failure and arrhythmogenesis. J Physiol (2009) 1.01
In vivo natriuretic peptide reporter assay identifies chemical modifiers of hypertrophic cardiomyopathy signalling. Cardiovasc Res (2011) 1.01
Myocardial oxidative stress contributes to transgenic β₂-adrenoceptor activation-induced cardiomyopathy and heart failure. Br J Pharmacol (2011) 1.00
Beta-blocker use for the stages of heart failure. Mayo Clin Proc (2009) 1.00
Implementation of evidence-based therapy in patients with systolic heart failure from 1998-2000. Clin Res Cardiol (2006) 0.99
Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Eur J Heart Fail (2014) 0.98
Cardiac alpha1-adrenergic receptors: novel aspects of expression, signaling mechanisms, physiologic function, and clinical importance. Pharmacol Rev (2013) 0.96
Early combined treatment with sildenafil and adipose-derived mesenchymal stem cells preserves heart function in rat dilated cardiomyopathy. J Transl Med (2010) 0.96
Renal dysfunction in acute and chronic heart failure: prevalence, incidence and prognosis. Heart Fail Rev (2012) 0.96
The Role of Inhibitory G Proteins and Regulators of G Protein Signaling in the in vivo Control of Heart Rate and Predisposition to Cardiac Arrhythmias. Front Physiol (2012) 0.95
Rationale, Design, Methodology and Hospital Characteristics of the First Gulf Acute Heart Failure Registry (Gulf CARE). Heart Views (2014) 0.93
Beta-blockers in heart failure: are pharmacological differences clinically important? Heart Fail Rev (2004) 0.93
Use of carvedilol in hypertension: an update. Vasc Health Risk Manag (2012) 0.92
Biological Heart Rate Reduction Through Genetic Suppression of Gα(s) Protein in the Sinoatrial Node. J Am Heart Assoc (2012) 0.92
Absence of the inhibitory G-protein Galphai2 predisposes to ventricular cardiac arrhythmia. Circ Arrhythm Electrophysiol (2010) 0.90
New advances in beta-blocker therapy in heart failure. Front Physiol (2013) 0.90
Association of beta-adrenergic receptor polymorphisms and mortality in carvedilol-treated chronic heart-failure patients. Br J Clin Pharmacol (2011) 0.90
A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics. Clin Pharmacol Ther (2013) 0.90
A personalized BEST: characterization of latent clinical classes of nonischemic heart failure that predict outcomes and response to bucindolol. PLoS One (2012) 0.89
Targeting ryanodine receptors for anti-arrhythmic therapy. Acta Pharmacol Sin (2011) 0.88
Novel postoperative use of beta-blocking medication for infants with left ventricular outflow obstruction and diastolic myocardial dysfunction. Pediatr Cardiol (2012) 0.88
Antihypertensive medications: benefits of blood pressure lowering and hazards of metabolic effects. Expert Rev Cardiovasc Ther (2009) 0.88
Effects of carvedilol on left ventricular remodelling in chronic stable heart failure: a cardiovascular magnetic resonance study. Heart (2004) 0.88
Cardiac innervation and sudden cardiac death. Curr Cardiol Rev (2009) 0.87
Comparative effectiveness research in heart failure therapies: women, elderly patients, and patients with kidney disease. Heart Fail Clin (2012) 0.87
Effect of a community heart failure clinic on uptake of beta blockers by patients with obstructive airways disease and heart failure. Heart (2005) 0.86
Mechanisms of the beneficial effects of beta-adrenoceptor antagonists in congestive heart failure. Exp Clin Cardiol (2010) 0.86
Impact of race on cumulative exposure to antihypertensive medications in dialysis. Am J Hypertens (2012) 0.86
Heart rate control with adrenergic blockade: clinical outcomes in cardiovascular medicine. Vasc Health Risk Manag (2010) 0.85
Time course of left ventricular reverse remodeling in response to pharmacotherapy: clinical implication for heart failure prognosis in patients with idiopathic dilated cardiomyopathy. Heart Vessels (2015) 0.84
Central mechanisms of abnormal sympathoexcitation in chronic heart failure. Cardiol Res Pract (2012) 0.84
Multiple interactions between the alpha 2C- and beta1-adrenergic receptors influence heart failure survival. BMC Med Genet (2008) 0.84
Congestive heart failure in Indians: how do we improve diagnosis & management? Indian J Med Res (2010) 0.84
DEFEAT heart failure: assessment and management of heart failure in nursing homes made easy. J Am Med Dir Assoc (2008) 0.84
Abnormal nocturnal heart rate variability response among chronic kidney disease and dialysis patients during wakefulness and sleep. Nephrol Dial Transplant (2010) 0.84
Discovery of GPCR ligands for probing signal transduction pathways. Front Pharmacol (2014) 0.84
Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF). Eur J Heart Fail (2013) 0.84
Metoprolol compared to carvedilol deteriorates insulin-stimulated endothelial function in patients with type 2 diabetes - a randomized study. Cardiovasc Diabetol (2010) 0.84
Predicting in vivo cardiovascular properties of β-blockers from cellular assays: a quantitative comparison of cellular and cardiovascular pharmacological responses. FASEB J (2011) 0.84
PDE3 inhibition in dilated cardiomyopathy. Curr Opin Pharmacol (2011) 0.84
Carvedilol in the treatment of chronic heart failure: lessons from the Carvedilol Or Metoprolol European Trial. Vasc Health Risk Manag (2007) 0.83
Chronic heart failure: beta-blockers and pharmacogenetics. Eur J Clin Pharmacol (2008) 0.83
Devices in the management of advanced, chronic heart failure. Nat Rev Cardiol (2012) 0.83
β-Blocker dialyzability and mortality in older patients receiving hemodialysis. J Am Soc Nephrol (2014) 0.83
The effects of beta blockers on morbidity and mortality in heart failure. Heart Fail Rev (2004) 0.83
In-hospital cardiology consultation and evidence-based care for nursing home residents with heart failure. J Am Med Dir Assoc (2011) 0.83
Anti-inflammatory and pro-angiogenic effects of beta blockers in a canine model of chronic ischemic cardiomyopathy: comparison between carvedilol and metoprolol. Basic Res Cardiol (2013) 0.83
Drug therapy for heart failure in older patients-what do they want? J Geriatr Cardiol (2015) 0.82
Prognostic significance of beta-blocker up-titration in conjunction with cardiac resynchronization therapy in heart failure management. Heart Vessels (2015) 0.82
Comparison of carvedilol and metoprolol in patients with acute myocardial infarction undergoing primary coronary intervention--the PASSAT Study. Clin Res Cardiol (2006) 0.82
Carvedilol targets human K2P 3.1 (TASK1) K+ leak channels. Br J Pharmacol (2011) 0.82
S49G and R389G polymorphisms of the β₁-adrenergic receptor influence signaling via the cAMP-PKA and ERK pathways. Physiol Genomics (2013) 0.82
Biased β2 -adrenoceptor signalling in heart failure: pathophysiology and drug discovery. Br J Pharmacol (2014) 0.82
Executive summary of the African-American Initiative. MedGenMed (2007) 0.82
Effect of β-blockers on platelet aggregation: a systematic review and meta-analysis. Br J Clin Pharmacol (2014) 0.82
ESC-CHF: guidelines for the aspirational and the practical. Heart (2006) 0.82
GENETIC CAUSES OF DILATED CARDIOMYOPATHY. Prog Pediatr Cardiol (2014) 0.82
COMET: a proposed mechanism of action to explain the results and concerns about dose. Lancet (2003) 0.81
Controlled-release carvedilol in the management of systemic hypertension and myocardial dysfunction. Vasc Health Risk Manag (2008) 0.81
Cardiac fibrosis detected by magnetic resonance imaging on predicting time course diversity of left ventricular reverse remodeling in patients with idiopathic dilated cardiomyopathy. Heart Vessels (2016) 0.81
Sex-related differences in heart failure and beta-blockers. Heart Fail Rev (2004) 0.81
Comparison of HERG channel blocking effects of various beta-blockers-- implication for clinical strategy. Br J Pharmacol (2006) 0.81
Carvedilol analogue inhibits triggered activities evoked by both early and delayed afterdepolarizations. Heart Rhythm (2012) 0.81
Management of patients with non-ischaemic cardiomyopathy. Heart (2007) 0.81
Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med (2007) 18.78
Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2009) 18.03
Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med (2010) 14.43
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73
Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med (2014) 11.77
Guidelines on the management of valvular heart disease (version 2012). Eur Heart J (2012) 10.70
Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med (2006) 10.65
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med (2003) 10.57
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet (2003) 9.98
Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med (2008) 9.62
Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med (2011) 8.93
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet (2009) 8.54
Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med (2009) 8.51
Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA (2002) 8.28
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet (2010) 8.17
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet (2003) 8.12
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. N Engl J Med (2007) 7.86
Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J (2005) 7.75
Rosuvastatin in older patients with systolic heart failure. N Engl J Med (2007) 7.55
Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation (2006) 7.01
Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet (2012) 6.42
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA (2007) 6.25
Truncations of titin causing dilated cardiomyopathy. N Engl J Med (2012) 6.07
Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation (2003) 5.85
Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J (2006) 5.79
Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg (2012) 5.49
Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet (2009) 5.23
Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet (2007) 5.21
Telemonitoring or structured telephone support programmes for patients with chronic heart failure: systematic review and meta-analysis. BMJ (2007) 5.02
Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation (2011) 4.90
Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol (2007) 4.74
Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med (2003) 4.72
Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med (2012) 4.69
EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J (2006) 4.57
Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med (2010) 4.52
Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA (2007) 4.30
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med (2010) 4.01
Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation (2006) 3.85
Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J (2011) 3.72
Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet (2005) 3.67
Decreasing one-year mortality and hospitalization rates for heart failure in Sweden; Data from the Swedish Hospital Discharge Registry 1988 to 2000. Eur Heart J (2004) 3.65
Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol (2004) 3.58
Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J (2005) 3.50
Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: a systematic review. Eur Heart J (2005) 3.50
Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med (2008) 3.49
Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation (2011) 3.48
Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure. Am J Med (2013) 3.46
Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet (2004) 3.40
State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail (2008) 3.35
Prognosis among healthy individuals discharged with a primary diagnosis of syncope. J Am Coll Cardiol (2012) 3.33
Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. JAMA (2008) 3.31
Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation (2004) 3.30
Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation (2012) 3.30
Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation (2008) 3.23
Mutations in Cypher/ZASP in patients with dilated cardiomyopathy and left ventricular non-compaction. J Am Coll Cardiol (2003) 3.20
Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation (2009) 3.18
Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J (2004) 3.14
Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol (2013) 3.06
Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation (2007) 2.95
The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis (2011) 2.95
The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. Eur Heart J (2005) 2.92
Relation of nonsteroidal anti-inflammatory drugs to serious bleeding and thromboembolism risk in patients with atrial fibrillation receiving antithrombotic therapy: a nationwide cohort study. Ann Intern Med (2014) 2.91
Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med (2010) 2.90
Masked hypertension in diabetes mellitus: treatment implications for clinical practice. Hypertension (2013) 2.89
Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. Eur Heart J (2010) 2.86
Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding. JAMA (2012) 2.85
Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet (2010) 2.80
Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet (2009) 2.79
Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation (2005) 2.78
Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail (2007) 2.77
Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation (2004) 2.73
Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med (2010) 2.71
Risk stratification with the risk chart from the European Society of Hypertension compared with SCORE in the general population. J Hypertens (2009) 2.71
Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation (2002) 2.69